Last reviewed · How we verify
Vitamin K antagonist (VKA) (vitamin-k-antagonist-vka)
Pfizer Inc. is developing a Vitamin K antagonist (VKA) in the preclinical phase for the prophylaxis and treatment of venous thrombosis and thromboembolism. The key competitive advantage of VKAs lies in their well-established mechanism for preventing blood clots, though the specific mechanism of Pfizer's VKA is not detailed. Primary risks include strong competition from established anticoagulants such as Dabigatran, Rivaroxaban, Apixaban, and Betrixaban.
At a glance
| Generic name | vitamin-k-antagonist-vka |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Anticoagulant |
| Target | Vitamin K-dependent clotting factors |
| Phase | preclinical |
Approved indications
- Prophylaxis and treatment of venous thrombosis and thromboembolism
- Prophylaxis and treatment of pulmonary embolism
- Prophylaxis and treatment of deep vein thrombosis
- Prophylaxis and treatment of myocardial infarction
- Prophylaxis and treatment of stroke
- Prophylaxis and treatment of atrial fibrillation
- Prophylaxis and treatment of mechanical heart valves
- Prophylaxis and treatment of warfarin-induced skin necrosis
- Prophylaxis and treatment of coumarin-induced skin necrosis
- Prophylaxis and treatment of antiphospholipid syndrome
- Prophylaxis and treatment of heparin-induced thrombocytopenia
- Prophylaxis and treatment of cancer-associated thrombosis
- Prophylaxis and treatment of postoperative thrombosis
- Prophylaxis and treatment of recurrent venous thromboembolism
- Prophylaxis and treatment of recurrent pulmonary embolism
- Prophylaxis and treatment of recurrent deep vein thrombosis
- Prophylaxis and treatment of recurrent myocardial infarction
- Prophylaxis and treatment of recurrent stroke
- Prophylaxis and treatment of recurrent atrial fibrillation
- Prophylaxis and treatment of recurrent mechanical heart valves
Common side effects
Drug interactions
- Amiodarone
- Aspirin
- Azithromycin
- Cimetidine
- Clopidogrel
- Diltiazem
- Erythromycin
- Fluconazole
- Fluoxetine
- Isoniazid
- Ketoconazole
- Metronidazole
Key clinical trials
- SIMPLAAFY Clinical Trial (NA)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
- High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- Effect of Telitacicept on Antibody Titers in Primary APS Patients (PHASE2)
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
- The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin K antagonist (VKA) CI brief — competitive landscape report
- Vitamin K antagonist (VKA) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI